Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Medis Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1483)
Cancellation or suspension (26)
ARTG (21)
Listed medicine compliance report (5)
Prescription medicine registration (2)

Date

2026 (26)
2025 (58)
2024 (1215)
2023 (3)
2022 (29)
2021 (106)
2020 (31)
2019 (6)
2018 (3)
2017 (41)
2015 (2)
2014 (3)
2013 (1)
2012 (6)
2011 (6)
2009 (1)

Search

Sponsor content

1537 result(s) found, displaying 1351 to 1360

Suspended from ARTG - RANITIDINE-WT ranitidine (as hydrochloride) 300mg tablet blister pack (OF) Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
GLIMEPRO 3 glimepiride 3 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
GLIMEPRO 2 glimepiride 2 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
GLIMEPRO 1 glimepiride 1 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
APO-QUETIAPINE XR quetiapine (as fumarate) 50mg modified release tablets blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
APO-QUETIAPINE XR quetiapine (as fumarate) 300mg modified release tablets blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
APO-QUETIAPINE XR quetiapine (as fumarate) 200mg modified release tablets blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
APO-QUETIAPINE XR quetiapine (as fumarate) 400mg modified release tablets blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
IRINOTECAN ACT irinotecan hydrochloride trihydrate 500mg/25mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
IRINOTECAN ACT irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

16 June 2021

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd

Pages

First page
Previous page
…
Page 132
Page 133
Page 134
Page 135
Current page 136
Page 137
Page 138
Page 139
Page 140
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.